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IL-1 exists in two forms, termed IL-1a and IL-1b, which
exert similar effects in a number of biologic models.
Recently, there have been reports of some differences in
the activities of these two species in some systems.
To address this issue with regard to Langerhans cells,
Langerhans cell-enriched preparations of epidermal cells
were treated with either IL-1a or IL-1b before pulsing
with S1509a tumor-associated antigens and subsequent
use for immunization of naı¨ve mice to S1509a. While
epidermal cells treated with 100 U IL-1b per ml were
able to induce protective tumor immunity (as indicated
by the rejection of a subsequent tumor challenge with
viable S1509a tumor cells), epidermal cells treated with
100 U IL-1a per ml failed to confer protective immunity.
At 1000 U per ml, IL-1b also inhibited the ability of
epidermal cells to induce tumor immunity. To investigate
the effects of the two IL-1 forms on elicitation of tumor
immunity, naı¨ve mice were immunized against the
S1509a tumor by s.c. injection of dead S1509a cells.
IL-1 plays an important role in immune and inflammatoryreactions. There are two different forms of IL-1, IL-1α andIL-1β, which have similar activities in many systems (Dinarello,1988, 1991). Within the murine skin, keratinocytes are able toproduce large amounts of IL-1α, whereas IL-1β is expressed
primarily by macrophages and as an early event of Langerhans cell
activation (Toshiyuki et al, 1995). IL-1α production can be significantly
enhanced by chemical or mechanical stimuli and by ultraviolet radiation
(UVR) (Gahring et al, 1981), and is thought to be important in the
regulation of inflammatory, proliferative, and immunologic events
(Dinarello and Wolff, 1993). Interestingly, IL-1α is induced by various
tumor promoters applied to the skin, suggesting a possible role of IL-
1α in the early development of skin cancer (Lee et al, 1993). IL-1β,
however, appears to be upregulated in Langerhans cells rapidly after
contact allergen exposure. Furthermore, after intradermal injection of
murine IL-1β into mouse ears, the gene expression of several biologic
response modifiers was upregulated in a way that mimicked the changes
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Epidermal cells enriched for Langerhans cells were treated
with either 100 U IL-1a or IL-1b per ml before tumor-
associated antigens-pulsing. Epidermal cells were then
washed and injected into a hind footpad of tumor immune
mice and 24 h footpad swelling was assessed as a measure
of delayed-type hypersensitivity. Exposure to IL-1a led
to suppressed elicitation of delayed-type hypersensitivity,
whereas IL-1b treated epidermal cells elicited a normal
(100 U per ml) or enhanced (1000 U per ml) level
of delayed-type hypersensitivity. Previous experiments
indicated that the suppressive effects of IL-1a on induc-
tion of immunity may be mediated by TNFa. Therefore,
the ability of IL-1a or IL-1b to induce epidermal cell
production of TNFa was assessed. IL-1a induced epi-
dermal cells to secrete significantly higher amounts of
TNFa protein compared with stimulation with IL-1b.
IL-1a and IL-1b appear to differentially regulate epi-
dermal cell antigen presenting capability. Key words:
Langerhans cells/TNFa/tumor immunology. J Invest Dermatol
111:609–615, 1998
caused by allergen exposure (Enk et al, 1993). Epidermal cells from
IL-1β injected sites demonstrated increased alloantigen-presenting
ability, whereas epidermal cells from IL-1α injected sites had decreased
alloantigen-presenting function. Also, after systemic administration, IL-
1β could enhance the number of specific antibody producing cells in
the spleen of mice immunized to specific antigen, whereas IL-1α
inhibited this antibody response (Boraschi et al, 1990). Taken together,
these findings are highly suggestive for a dichotomy in the activity of
the two interleukins.
Langerhans cells, the principal antigen-presenting cells within the
epidermis, are able to induce and elicit CD4-dependent immune
responses in vitro as well as in vivo (Inaba et al, 1986). Recently,
extensive research are centered around the role of Langerhans cells in
the development of tumor immunity. Langerhans cells are capable of
presenting tumor-associated antigens (TAA) for the induction of both
primary and the elicitation of secondary immune responses (Grabbe
et al, 1991). Interestingly, exposure of Langerhans cells to granulocyte
macrophage-colony stimulating factor (GM-CSF) seems to be a require-
ment for successful priming of naı¨ve animals for substantial tumor
immunity. Several carcinogens, including UVR, are known to alter
the number and morphology of Langerhans cells (Aberer et al, 1981;
Stingl et al, 1983; Greene et al, 1984). UVR has been of particular
interest because it is the most relevant agent with regard to human
nonmelanoma skin cancer. At skin sites irradiated in vivo the induction
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of immunity against epicutaneously applied haptens is suppressed
(Shimizu and Streilein, 1994). At higher doses of UVR the ability to
induce contact or delayed-type hypersensitivity (DTH) is systemically
impaired (Ullrich, 1986; Molendijk et al, 1987). The role of cytokines
in these effects is suggested by the ability of UVR to induce the release
of cytokines from keratinocytes (Ullrich, 1995a, b). Several of those
factors, including interleukin-10 (IL-10), tumor necrosis factor-α
(TNFα), and interferon-γ (IFNγ), were able to inhibit or, in the case
of GM-CSF, to enhance antigen-presenting function of epidermal
Langerhans cells. In this context previous work from our laboratory
demonstrated that IL-1α is able to suppress the ability of epidermal
antigen-presenting cells to present TAA for protective tumor immunity
and that this inhibition can be abrogated by anti-TNFα (Grabbe
et al, 1994).
In this study, we have investigated the issue of functional distinction
between IL-1α and IL-1β with regard to presentation of tumor
antigens. To address this question, we have examined the ability of
either IL-1α or IL-1β to regulate Langerhans cell presentation of TAA
for in vivo anti-tumor immunity. Moreover, by using epidermal cell
preparations pulsed with TAA to elicit DTH activity in tumor immune
mice, we used this system to examine separately the ability of the two
IL-1 forms to regulate Langerhans cell presentation for induction of
primary and elicitation of secondary immune responses.
MATERIALS AND METHODS
Mice Five to 8 wk old female (BALB/C 3 A/J)F1[CAF1](H-2
d/a) mice were
obtained from The Jackson Laboratory (Bar Harbor, ME).
Tumors The S1509a methylcholanthrene-induced spindle cell tumor line,
originally derived from A/J mice, was kindly provided by Dr. Mark I. Greene
(University of Pennsylvania, Philadelphia, PA). It was maintained in tissue
culture at 37°C and 5% CO2 in RPMI-1640 supplemented with 10% heat
inactivated fetal calf serum (Gibco Laboratories, Grand Island, NY), 100 U
penicillin per ml, 100 mg streptomycin per ml, 0.1 mM essential and nonessential
amino acids, 2 mM L-glutamine, 1 mM sodium pyruvate, and 0.01 M HEPES
buffer [‘‘complete medium’’ (CM)]. S1509a usually grows progressively in
normal syngeneic recipients and has been demonstrated to induce a variety of
immunologic responses in the host (Grabbe et al, 1991).
Reagents Cytokines and growth factors used in this study included recombin-
ant murine GM-CSF, recombinant murine IL-1β (Genzyme, Cambridge, MA;
specific activity, .1 3 107 U per mg), recombinant murine IL-1α (Genzyme;
specific activity, .1 3 107 U per mg), and EGF (Collaborative Biomedical
Products, Bedford, MA). The two IL-1 forms were tested for endotoxin
contamination with an E-TOXATE assay (Sigma, St. Louis, MO) and were
found to be endotoxin negative. Monoclonal rat anti-mouse IL-1 receptor type
1 and anti-TNFα antibodies were purchased from Genzyme and used according
to the manufacturer’s instructions for inhibition of IL-1α bioactivity. Anti-IL-
1β was purchased from R&D Systems (Abington, U.K.). Anti-Thy 1.2
monoclonal antibody (clone NEI-001 TS) was obtained from Sigma and used
at 1:2000. Low toxicity rabbit complement was obtained from Cedarlane
Laboratories (Hornby, Ontario, Canada) and used at 1:40 in phosphate-buffered
saline. Enzymes used during preparation and dissociation of epidermal cells
were dispase (Collaborative Research, Bedford, MA), DNase (Sigma), and
trypsin (Gibco, Grand Island, NY). A commercially available enzyme-linked
immunosorbent assay for murine TNFα/β (Genzyme) had a sensitivity of 10 pg
per ml and was utilized according to the manufacturer’s instructions. For
culturing primary keratinocytes, 10 cm tissue culture dishes were coated with
1 mg bovine serum albumin per ml (Boehringer, Indianapolis, IN), 10 mM
HEPES buffer (Gibco), and 60 mg Vitrogen 100 per ml (Celtrix, Palo Alto,
CA) in Hank’s balanced salt solution (Gibco).
Soluble TAA were prepared from freeze-thaw lysates of S1509a tumor cells
as described elsewhere (Grabbe et al, 1991). Briefly, S1509a cells (107 per ml
in complete medium) were disrupted by three freeze-thaw cycles and centrifuged
at 600 3 g for 20 min. The supernatant was collected and spun again at
13,000 3 g for 1 h. The remaining supernatant was used as a source of
soluble TAA.
Preparation of epidermal cells and immunization protocol Epidermal
cells were prepared using a standard protocol as described (Grabbe et al, 1991).
Briefly, truncal skins of shaved and chemically depilated (Neet, Whitehall
Laboratories, New York, NY) mice were removed and depleted of s.c. fat and
panniculus carnosus. The skins were floated dermis side down on 0.5 U dispase
per ml and 0.4% trypsin in Ca11/Mg11-free phosphate-buffered saline for
40 min at 37°C; epidermal sheets were then collected and dissociated by gentle
strirring for 20 min. The resulting epidermal cells were filtered through nylon
gauze (Nitex, Tetco, Elmsford, NY) and washed. Thy 11 cells were deleted
by incubation in anti-Thy 1.2 monoclonal antibody for 30 min on ice, followed
by washing and subsequent incubation in low-toxicity rabbit complement for
30 min at 37°C. Dead cells were removed by treatment with 0.05% trypsin
and 80 mg DNase per ml in Ca11/Mg11-free phosphate-buffered saline for
5 min at room temperature. Typically, the epidermal cell population contained
between 5% and 15% I-A1 cells. Viability and percentage of I-A1 cells were
assessed by flow cytometry immediately before injection into mice, and
differences in I-A1 cell percentage between groups within experiments were
negligible.
In order to rule out effects of IL-1α or IL-1β on epidermal cell viability,
epidermal cells were cultured for 16 h in 100 U per ml and 1000 U per ml of
either IL-1α or IL-1β. Controls were incubated in CM. There were no
differences between the viability of IL-1 treated epidermal cells compared with
controls. Also, the proportion of Ia1 cells among the groups was not altered
by IL-1 treatment as investigated by flow cytometry.
Epidermal cells were then treated with either IL-1α or IL-1β in CM
containing 50 U GM-CSF per ml for 16 h at 37°C. In another experiment an
additional group of epidermal cells was cultured for 1 h at 37°C with monoclonal
rat anti-mouse IL-1 receptor type 1 antibodies before washing and incubation
in 100 U IL-1α per ml plus 50 U GM-CSF per ml in CM for 16 h. Another
group of epidermal cells was incubated with anti-IL-1 for 1 h, washed, and
cultured in 50 U GM-CSF per ml in CM for 16 h. Treatment of epidermal
cells with neutralizing anti-TNFα antibodies was performed at a concentration
of 1:1000 during all incubation periods until injection of epidermal cells into
mice. Control cells were cultured only in CM containing GM-CSF. After the
incubation periods dead cells were depleted, epidermal cells were washed three
times, and incubated in CM containing TAA or in CM alone (negative control)
for 2 h at 37°C. After TAA-pulsing, the epidermal cells were washed extensively
to remove unbound TAA. Two hundred thousand epidermal cells were then
injected s.c. into each naı¨ve recipient on the lower back. This immunization
was repeated three times at weekly intervals. One week after the last immuniza-
tion, mice were challenged with 2 3 106 live S1509a tumor cells s.c. on the lower
lateral abdomen and tumor growth was assessed every 48 h by measurement with
a Vernier caliper.
Earlier studies showed that epidermal cells treated with GM-CSF overnight
and pulsed with TAA generate tumor immunity in immunized mice, leading
to immunologic rejection of the tumor over a period of 7–14 d (Grabbe et al,
1991). The specificity of tumor immunity in this system was previously
demonstrated by showing that immunization with tumor cell lysates from an
unrelated tumor line (UV-5496–1) does not lead to immunity against S1509a
(Grabbe et al, 1991).
Elicitation of S1509a tumor immunity and measurement of DTH Mice
were immunized against S1509a by three injections of 0.5–1.0 3 106 dead
S1509a (killed by repetitive freeze-thawing) s.c. at 5–7 d intervals. Generation
of protective immunity in these mice was confirmed by rejection of a subsequent
tumor challenge and induction of DTH against this tumor (data not shown).
Epidermal cells from naı¨ve donor mice were generated and Thy-11 cells
depleted as described above. Epidermal cells were then pulsed with S1509a
TAA for 2 h, washed extensively, and 5 3 105 cells were then injected into a
hind footpad of tumor-immune mice. Some groups of epidermal cells were
treated with 100 U IL-1α or IL-1β per ml for 3 h before TAA pulsing. Specific
footpad swelling was measured as the mean difference between the footpad
thickness of the injected versus the uninjected side 24 h after challenge.
For heat-inactivation, 1000 U IL-1β per ml was heated at 60°C for 30 min.
Thymocyte proliferation assay Thymocytes were aseptically harvested
from 3 wk old C3H/HeJ mice. Samples of 1 3 105 thymocytes were cultured
in 200 µl of CM containing 4 mg PHA per ml and either IL-1α or IL-1β at
concentrations 1, 10, 100, and 1000 U per ml. After 72 h of incubation at
37°C in 5% CO2, cells were pulsed with 1 µCi of [3H]TdR and incubated for
an additional 6 h. At that time cells were harvested with a semiautomated cell
harvester (Harvester 96, Model II, Tomtech, Orange, CT). Incorporation of
[3H]TdR was examined by liquid szintillation counting.
Culture of epidermal cells Mouse primary keratinocytes were prepared
from 4 to 8 wk old CAF1 mice as above and maintained in low-calcium
(0.05 mM) minimal essential medium supplemented with 4% Chelex-treated
fetal calf serum and epidermal growth factor (10 ng per ml; Collaborative
Research, Cambridge, MA) in collagen type I coated tissue culture dishes. IL-
1α or IL-1β (10, 100, 1000 U per ml) were added to the medium from the
beginning of the culturing to the medium. Supernatants were harvested after
24 h and TNFα protein content evaluated with a TNFα/β enzyme-linked
immunosorbent assay (Genzyme, Cambridge, MA).
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Data generation and statistical evaluation Tumor volumes were calculated
as the product of the maximal tumor diameter in three perpendicular directions,
measured with a Vernier caliper. This method was previously confirmed to
correlate well with the tumor weight (Grabbe et al, 1991). To avoid unnecessary
pain to the experimental animals, mice were sacrificed after the tumor volume
exceeded 1000 mm3. To evaluate statistical differences between the mean tumor
volume in the various experimental groups, the ‘‘best-fit’’ slope of the tumor
growth in each animal was determined using Cricket Graph software (version
1.3.2, Cricket Software, Malvern PA) on a Macintosh computer and the
significance of differences between the means of the slopes for the groups of
interest tested by the two-tailed Student’s t test for unpaired data. The significance
of differences between the mean values obtained for DTH experiments was
assessed by the two-tailed Student’s t test for unpaired data.
RESULTS
Dichotomy in the effects of IL-1a and IL-1b on the induction
of tumor immunity To examine the effects of IL-1α and IL-1β
on the ability of epidermal antigen-presenting cells to present TAA for
the induction of protective immunity in naı¨ve recipient mice, epidermal
cells were prepared and enriched for Langerhans cells as described.
One group of cells was incubated in 100 U IL-1α per ml and 50 U
GM-CSF per ml, whereas the other group was cultured in 100 U IL-
1β and GM-CSF per ml for 16 h. Those IL-1α and IL-1β concentrations
induce identical stimulation in a thymocyte in vitro assay (data not
shown). Epidermal cells were then washed, pulsed with TAA, washed
again, and injected s.c. into naı¨ve mice for immunizations. Control
groups were incubated in GM-CSF for 16 h, washed, and either pulsed
(positive control) or not pulsed (negative control) with TAA before
injection. These procedures were repeated with each group at weekly
intervals for 3 wk. One week after the last immunization all mice were
challenged with viable S1509a tumor cells at a site different from that
of immunization and tumor growth was scored over time. Figure 1(A)
shows that GM-CSF-treated epidermal cells can effectively present
TAA for induction of substantial immunity (group A), as reported
previously. GM-CSF is required for epidermal cells to present TAA
efficiently for induction of tumor immunity in this system; thus
exposure to GM-CSF was performed in all experimental groups.
Exposure of epidermal cells to IL-1α inhibited their ability to induce
protective tumor immunity, whereas culture in IL-1β did not suppress
epidermal antigen-presenting cell function. The inhibition of the
induction of tumor immunity by IL-1α was abrogated by neutralizing
anti-TNFα antibodies (Fig 1B, group D). These results were observed
in three of three experiments.
Epidermal cells were prepared, enriched for Langerhans cells, and
divided into three groups (Fig 2). One group of cells was incubated
in IL-1α and GM-CSF as above (Fig 1, group C), another group of
cells was incubated in rat anti-mouse IL-1 receptor type 1 antibody
for 30 min at 37°C followed by addition of IL-1α and GM-CSF for
an additional 16 h of incubation. The third group of epidermal cells
was pretreated with anti-IL-1 as above and then cultured only in GM-
CSF. All groups were washed, pulsed with TAA, washed again, and
used for immunization. Positive and negative control groups were
treated as described before. Figure 2, group D, demonstrates that
preincubation of epidermal cells in anti-IL1 receptor type 1 antibody
abrogated the inhibitory effects of IL-1α on the induction of tumor
immunity by epidermal cells. Pretreatment of epidermal cells with
anti-IL-1R1 alone did not result in a significant suppression (Fig 2,
group E).
IL-1a induces a greater production of TNFa by epidermal cells
than IL-1b According to previous studies in our laboratory, the
suppressive effects of IL-1α on induction of immunity could be
inhibited by anti-TNFα (Grabbe et al, 1994). We therefore investigated
the modulatory effects of IL-1α and IL-1β on the production of TNFα
by cultured murine keratinocytes. Keratinocytes were cultured at a
concentration of 0.8 3 106 per ml for 24 h in low-Ca21 medium in
the presence of 10, 100, and 1000 U per ml of either IL-1α or IL-1β
in collagen type I coated tissue-culture dishes. Control epidermal cell
cultures were incubated in medium alone for the same amount of
time. Afterwards, supernatants were collected and assayed for the
presence of TNFα protein with a TNFα enzyme-linked immunosorb-
Figure 1. Differential effects of IL-1a and IL-1b on epidermal cell
presentation of TAA for induction of immunity. (A) Epidermal cells were
incubated in 50 U GM-CSF per ml plus either 100 U IL-1α per ml (group
C) or 100 U IL-1β per ml (group D) for 16 h. Epidermal cells were then
pulsed with TAA as described in Materials and Methods. Control groups were
cultured in GM-CSF alone and either pulsed with TAA (group A) or not
(group B). Groups of mice were immunized with 2 3 105 of these differentially
treated epidermal cells at weekly intervals for a total of three immunizations.
All mice were challenged with 2 3 106 viable S1509a tumor cells 1 wk after
the last immunization and tumor growth was scored over time. The graph
shows the mean tumor volume in mice immunized with differentially treated
epidermal cells. p , 0.001 for A versus B, C; not significant for A versus D. (B)
Epidermal cells were incubated in 50 U GM-CSF per ml plus either 100 U
IL-1α per ml (group C) or 100 U IL-1α per ml plus anti-TNFα (group D)
for 16 h. Epidermal cells were then pulsed with TAA as described. Control
groups were cultured in GM-CSF alone and either pulsed with TAA (group
A) or not pulsed (group B). Immunization was performed as above. p , 0.001
for A versus B, C; not significant for A versus D, E.
ent assay. Table I shows that IL-1α induced dose dependently more
TNFα compared with IL-1β. These data are from three independent
experiments.
A high concentration of IL-1b can inhibit induction of tumor
immunity Taking the experimental data from Table I into considera-
tion, we hypothesized that epidermal antigen-presenting cell function
might be suppressible by IL-1β if a much higher concentration was
used in order to stimulate sufficient TNFα production. To test this
hypothesis, epidermal cells were prepared, enriched for Langerhans
cells, and incubated in 1000 U per ml or 100 U per ml of IL-1β
without GM-CSF for 16 h. Control groups of epidermal cells were
treated as above. After washing and pulsing with TAA, epidermal cells
were used to immunize naı¨ve mice three times at weekly intervals. In
separate groups, Langerhans cell-enriched epidermal cells were prepared
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Figure 2. The suppressive effects of IL-1a could be abrogated with
anti-IL-1a type 1 receptor antibody. In this experiment epidermal cells
were incubated with anti-IL-1α type 1 receptor antibody for 30 min before
100 U IL-1α per ml and 50 U GM-CSF per ml were added (group D). Other
groups were treated either with IL-1α plus GM-CSF (group C) or with anti-
IL-1α plus GM-CSF (group E). Subsequently, these differentially treated
epidermal cells were pulsed with TAA and used for immunization. Control
groups of mice were treated and immunized and challenged as was described
in the legend to Fig 1. p , 0.001 for A versus B, C; not significant for A versus
D, E.
Table I. IL-1a is a stronger inducer of TNFa from epidermal
cells than IL-1ba
TNF content of
Concentration supernatants
Cytokine (U per ml) (pg per ml) p valueb
None – 38.8 6 35.5
IL-1α 10 94.1 6 29.3 –
IL-1β 10 85.6 6 34.3 0.171
IL-1α 100 222.4 6 10.1 –
IL-1β 100 97.3 6 31.0 0.009
IL-1α 1000 669.0 6 115.2 –
IL-1β 1000 181.5 6 88.1 0.015
a800,000 CAF1 epidermal cells per ml were cultured in medium alone or cytokines as
indicated for 24 h. Supernatants were then collected and assayed by enzyme-linked
immunosorbent assay for TNF content.
bIL-1α versus IL-1β at each concentration.
and treated with 1000 U IL-1β per ml in the presence of 50 U GM-
CSF per ml. Control groups were treated as described and all groups
of differentially cultured epidermal cells were, after washing and TAA
pulsing, used for immunization as above. Figure 3(A, groups C and
D) demonstrates that culture of Langerhans cell-enriched epidermal
cells in either 100 U per ml or 1000 U per ml of IL-1β without the
addition of GM-CSF fails to give epidermal cells the capability of
inducing tumor immunity in this system. The data in Fig 3(B),
however, shows that at the concentration of 1000 U per ml, IL-1β
does inhibit the ability of GM-CSF-treated epidermal cells to induce
protective tumor immunity. These results were observed in three of
three experiments.
IL-1a but not IL-1b suppresses the elicitation of DTH to TAA
As the regulation of primary immune responses may differ significantly
from that of secondary immune responses, experiments were performed
to investigate the effects of IL-1α and IL-1β on TAA presentation by
epidermal cells in a primed system. For this purpose, we employed the
mouse footpad model of DTH to the S1509a tumor. Mice were
immunized three times at 5 d intervals by s.c. injection of tumor
Figure 3. Very high concentrations of IL-1b suppress epidermal cell
antigen-presenting function. (A) Epidermal cells were cultured in either
100 U per ml or 1000 U per ml of IL-1β alone before TAA pulsing and use
for immunizations. Control groups were treated as above. p , 0.001 for A
versus B, C, D. (B) In another experiment epidermal cells were coincubated
with 1000 U IL-1β per ml and 50 U GM-CSF per ml, washed and pulsed
with TAA, and washed again before immunization. Control groups as above.
p , 0.001 for A versus B, C.
fragments generated by repetitive freeze/thaw cycles of S1509a tumor
cells. Those mice were immune to a subsequent tumor challenge.
Groups of mice were challenged 5 d after the last immunization by
injection of TAA-coupled epidermal cells into one hind footpad, and
24 h DTH was assessed as the difference in footpad thickness between
the injected versus noninjected site. To study the effects of IL-1α and
IL-1β on this system, epidermal cells that had been incubated in either
100 U IL-1α or IL-1β per ml, 1000 U IL-1β per ml or anti-TNFα
for 3 h prior to exposure to TAA were examined. Another group of
epidermal cells was pretreated with anti-TNFα for 30 min at 37°C,
before 1000 U IL-1β per ml were added. All differentially treated
epidermal cells were washed and pulsed with TAA for 2 h. Groups of
cells were washed again and then injected into a hind footpad of tumor
immune mice. After 24 h the DTH reaction was measured. For control
groups, epidermal cells were incubated in medium alone prior to
pulsing with TAA (positive control) or were not pulsed with TAA
(negative control) before injection.
Figure 4(A) demonstrates that IL-1α significantly and substantially
suppressed the elicitation phase of tumor immunity; however, incuba-
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Figure 4. Incubation of epidermal cells in IL-1a but not IL-1b inhibits
their ability to elicit DTH in tumor immune mice. (A) Mice were
immunized against S1509a by s.c. injection of 1 3 106 S1509a tumor cell
fragments (freeze/thaw S1509a lysates) three times at 5 d intervals. One week
after the last immunization, mice were challenged for a DTH response by
injection of 5 3 105 epidermal cells treated as below and footpad swelling
assessed as a measure of DTH response 24 h later. Epidermal cells were incubated
in either CM plus 100 U IL-1α per ml, 100 U IL-1β per ml, 1000 U IL-1β
per ml, or anti-TNFα for 3 h. Another group was preincubated in anti-TNFα
for 30 min at 37°C before 1000 U IL-1β per ml were added. Control groups
were cultured for the same amount of time in CM only. Groups of differentially
treated cells were then washed and pulsed with TAA for an additional 2 h. The
control groups were not exposed to cytokines but were pulsed with TAA
(positive control) or not pulsed (negative control). Error bars 6 SEM. p , 0.001
for A versus B, C, E; not significant for A versus D, F, G. (B) Mice were
immunized as above. Challenge was performed with epidermal cells treated
with 100 U IL-1α per ml (group C), IL-1α and anti-TNFα (group D), or
anti-TNFα (group E). Controls were performed as described above. p , 0.001
for A versus B, C, D; not significant for A versus E.
Figure 5. Incubation of epidermal cells in neutralizing anti-IL-1b anti-
sera abrogates the increased DTH response induced by very high
concentrations of IL-1b. Several groups of mice were immunized against the
S1509a tumor as described. Langerhans cell-enriched epidermal cells were either
treated with 1000 U IL-1β per ml (group C), pretreated with anti-IL-1β for
30 min before 1000 U IL-1β per ml were added (group D), or cultured in
anti-IL-1β (group E) alone. Another group was exposed to heat-inactivated
(30 min at 60°C) IL-1β (group F). Controls were performed as above (groups
A and B). Subsequently, all groups were TAA pulsed and injected after extensive
washing into one hind footpad as described. Error bars 1 SEM. p , 0.001 for
A versus B, C; not significant for A versus D, E, F.
tion in IL-1β resulted in a slight, but not statistically significant, increase
of DTH reaction against S1509a TAA. These findings were observed
in three of three experiments. Interestingly, incubation with IL-1β at
doses large enough to induce significant TNFα protein production
(1000 U per ml) yielded a significantly increased DTH response to
TAA when compared with the positive control group. This augmenting
effect could be abrogated with neutralizing anti-TNFα; anti-TNFα
treatment alone had no effect. This result is in agreement with our
earlier report indicating that TNFα treatment of EC significantly
augments DTH responses. The suppressive effects of 100 U IL-1α per
ml, however, could not be abrogated by exposure to neutralizing anti-
TNFα antibodies (Fig 4B, group D). This suggests that at least for
the S1509a-DTH assay IL-1α treatment has strong inhibitory effects,
which dominate over the effects of the IL-1α-induced TNFα pro-
duction.
In order to rule out the possibility that endotoxin contamination
could account for our findings, an additional experiment was performed
in which IL-1β was heat-inactivated by incubation at 60°C for 30 min.
Tumor immune mice were injected with Langerhans cell-enriched
epidermal cells that were treated with 1000 U IL-1β, anti-IL-1β per
ml and 1000 U IL-1β, anti-IL-1β per ml alone or heat-inactivated IL-
1β. The data in Fig 5 (one of three independent experiments) shows
that anti-IL-1β treatment abrogated the augmentation of DTH to TAA
induced by treatment of epidermal cells with a high concentration of
IL-1β. Neither antibody exposure alone nor exposure to heat-
inactivated IL-1β had a significant effect on elicitation of DTH. These
data suggest that endotoxin contamination is unlikely to be responsible
for the effects demonstrated by the data in Fig 4.
DISCUSSION
The data presented herein indicate a dichotomy in the effects of IL-
1α and IL-1β on tumor antigen presentation by epidermal antigen-
presenting cells. In contrast to IL-1α, IL-1β at a concentration of
100 U per ml failed to inhibit either the induction or the elicitation
of tumor immunity in mice. By blocking the IL-1 type I receptor
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(80 kDa) with a monoclonal antibody prior to IL-1α incubation, IL-
1α-induced suppression of the induction of immunity could be
abrogated. Interestingly, freshly prepared epidermal cells produced
significantly more TNFα when stimulated with IL-1α than after IL-
1β stimulation. Earlier experiments performed by Grabbe et al showed
that the inhibition of the induction of tumor immunity by IL-1α
could be abrogated by anti-TNFα (Grabbe et al, 1994). Very high
concentrations of IL-1β (1000 U per ml) were able to inhibit the
induction of tumor immunity. These findings suggest that the difference
seen in the effects of IL-1α and IL-1β on induction of tumor immunity
may relate to the relative ability of the two cytokines to induce TNFα
production. Additionally, IL-1α inhibits presentation of TAA by
epidermal cells for elicitation of DTH, whereas IL-1β does not. Indeed,
at 1000 U IL-1β per ml, augmentation of the DTH response was seen.
This is similar to the augmentation observed in this primed system
with TNFα. These observations support the concept of a differential
regulation of primary versus secondary cellular immune responses. They
also suggest that the IL-1α effect in primed systems is not mediated
through TNFα and that inhibition by IL-1α dominates over the
TNFα effect.
The finding that IL-1α and IL-1β have very different effects on
antigen presentation by Langerhans cells has a number of important
implications. First, IL-1α in the epidermis is produced primarily by
keratinocytes, whereas IL-1β is produced by Langerhans cells. Thus,
keratinocytes may tend to downregulate antigen presentation by
Langerhans cells, and production of IL-1β by Langerhans cells may
promote antigen presentation. This idea is supported by the fact
that very early in contact hypersensitivity responses, IL-1β expression
rises rapidly (Enk et al, 1993). Production of IL-1α by keratinocytes
may play a role in limiting antigen presentation within the epidermis.
For example, IL-1α induction is known to occur after exposure to
ultraviolet radiation, a mediator of suppressed cellular immune
responses. The concept that IL-1α may play a role in UVR-
induced immunosuppression is supported by the knowledge that
IL-1α induces TNFα expression, a cytokine shown to play an
important role in UVR-mediated suppression of the induction of
contact hypersensitivity (reviewed by Kurimoto and Streilein, 1992;
Streilein, 1993).
Observations of differential activities of the two IL-1 forms have
been seen in other experimental systems. IL-1β enhanced the number
of specific antibody producing spleen cells in mice after specific antigen
stimulation, whereas IL-1α was inhibitory (Boraschi et al, 1990).
Furthermore, after injection of IL-1β into the skin, harvested
Langerhans cells were more potent stimulators in alloantigen presenta-
tion assays than Langerhans cells derived from noninjected skin (Enk
et al, 1993); however, Langerhans cells from IL-1α injected sites were
suppressed in alloantigen presenting ability. Additionally, intradermally
administered IL-1β led to an enhancement of major histocompatibility
complex class II expression.
IL-1α is present within the murine epidermis in substantial concentra-
tions. After midrange wavelength ultraviolet irradiation (280–320 nm)
of a murine keratinocyte cell line, PAM 212, Gahring et al demonstrated
convincingly that IL-1 release was upregulated (Gahring et al, 1984).
Increased levels of IL-1 were also detectable in the serum of UVB
treated mice. Serum concentrations peaked 48 h after irradiation and
returned to normal after 96 h. In another study, IL-1α mRNA
expression was found to be upregulated after application of several
tumor promoters on mouse skin (Lee et al, 1993). No significant
upregulation was seen after nontumor promoting phorbol esters or
analogs of tumor promoters were used. These findings in concert with
our observations, may suggest a role for IL-1α in inhibiting immune
recognition of incipient tumors within the epidermis.
IL-1β was originally found to be produced primarily by macrophages;
however, it was reported that IL-1β gene expression was upregulated
as an early event of Langerhans cell activation with antigen. The
physiologic concentration of IL-1β in the epidermis may be below
that which is necessary to inhibit antigen presentation. Indeed, the
work of Enk et al suggests it augments the induction of primary
immunity in situ (Enk et al, 1993).
IL-1 binds to two cell-surface receptors. The IL-1 type I receptor
is an 80 kDa protein with a larger cytoplasmatic domain than the
smaller 60 kDa IL-1 type II receptor (Dower et al, 1986, 1990).
The type I receptor mediates IL-1 effects, whereas the type II
receptor acts as a ‘‘decoy’’ and does not signal (Colotta et al, 1993).
In vivo many IL-1-responsive cells express relatively low concentrations
of the type I receptor. Within the skin, high levels of type II
receptors are expressed on basal epithelial cells. In our experiments
the suppressive effects of IL-1α on induction of tumor immunity
could be successfully blocked by preincubation of epidermal cells
in anti-IL-1 receptor type I antibodies or with anti-TNFα.
Interestingly in this context, is the report by Probert et al showing
that after systemic treatment with a neutralizing monoclonal murine
IL-1 receptor type I antibody, the development of TNF-induced
arthritis in an murine experimental model could be abrogated
(Probert et al, 1995). Moreover, serum TNF levels were significantly
lower in IL-1 receptor type I antibody treated mice than in isotype
control antibody treated mice.
Taken together these data suggest that, at least for the suppression
of the induction phase of tumor immunity, IL-1α signal transduction
is mediated through the type I receptor that results in the increased
release of TNFα. At very high concentrations, IL-1β might be
suppressive by itself or might induce enough TNFα to suppress the
induction phase of tumor immunity as well.
These data demonstrate a novel aspect in the differential regulation
of epidermal immunity by the two IL-1 forms.
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